Early access
Sign in
Taking people in Hong KongPhase 3

Aspirin Continued or Paused Around Colon Procedures in Moderate-Risk Heart Patients

Compares continuing versus pausing aspirin in adults undergoing colonoscopy or polypectomy.

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy
Status
Recruiting
Phase
Phase 3
People taking part
2,514 people, planned
Started
10 Feb 2026
Expected to end
31 Dec 2031
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Aspirin 80mg
  • Placebo Oral Tablet
Record updated
18 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who take aspirin (80mg daily or more) to prevent heart and blood vessel disease and who need a planned colonoscopy for colorectal cancer screening.

Age
18 years or older
Sex
All sexes can join
Disease stage
People who already have cardiovascular disease and take aspirin to prevent it from coming back (secondary prevention).
Earlier treatment
Must be taking aspirin 80mg daily or more. Must not have had a coronary stent within 6 months. Must not take anticoagulants or other antiplatelet drugs.

Main reasons for not taking part

  • Coronary stent of any type within 6 months
  • Cardiovascular event within 3 months
  • Taking anticoagulants (warfarin or NOAC) or other antiplatelet drugs (P2Y12 receptor antagonists)
  • Bleeding disorder such as hemophilia, von Willebrand's disease or coagulopathy from liver cirrhosis
  • Terminal cancer or terminal medical illness

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • patients receiving aspirin (80mg daily or more) for secondary prevention against cardiovascular diseases who require elective colonoscopy for colorectal cancer screening

Who cannot take part

  • patients who received a coronary stent of any type within 6 months
  • patients who had concurrent use of anticoagulants (warfarin or NOAC) or other antiplatelet drugs (P2Y12 receptor antagonists)
  • patient with bleeding diathesis e.g., hemophilia, von Willebrand's disease or coagulopathy from liver cirrhosis
  • patient with terminal malignancies or medical illnesses
  • patients who had a cardiovascular event within 3 months
  • patient who is unable or refuse to give consents

Where in Hong Kong

  • Prince of Wales HospitalHong Kong, Hong KongContact: James Lau, MDTaking people

About the trial

What the trial wants to find out

One in 4 adults between 50 and 80 reports taking regular aspirin. The prevalence of aspirin uses increases with age as well as co-morbid vascular diseases. Patients with cardiovascular diseases are at risk of developing colorectal neoplasms. In patients undergoing screening colonoscopy, interruption of aspirin is believed to be associated with increased cardiovascular events. Continuation of aspirin can however be associated with an increased risk of post-polypectomy bleeding. International guidelines on periendoscopy management recommend the continuation of aspirin based on evidence from cohort studies, mostly retrospective, suggesting that the rate of bleeding is low. Cardiovascular complications from aspirin interruption can lead to disabilities and occasional deaths. The cardiovascular risks following aspirin continuation or interruption in endoscopy have not been well studied. There has been no randomized study to compare either strategy. Endoscopists are divided on their opinion on whether to stop or to continue aspirin. The proposed large randomized controlled trial (RCT) is powered to detect small differences in both outcomes. Findings from this RCT will address this important question and inform our clinical practice.

The 2 groups in the trial

  • aspirinExisting treatment, for comparison

    8-day (-5, +3) supply of aspirin 80mg before and after colonoscopy

    Treatment: Aspirin 80mg

  • PlaceboPlacebo, for comparison

    8-day (-5, +3) supply of placebo 80mg before and after colonoscopy

    Treatment: Placebo Oral Tablet

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy; a Placebo-controlled Trial
Plain-language title
Aspirin Continued or Paused Around Colon Procedures in Moderate-Risk Heart PatientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
18 March 2026